Inogen, Inc (NASDAQ:INGN - Get Free Report)'s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $6.64 and traded as high as $6.73. Inogen shares last traded at $6.35, with a volume of 175,607 shares traded.
Analyst Ratings Changes
Several brokerages have recently commented on INGN. Needham & Company LLC raised Inogen from a "hold" rating to a "moderate buy" rating and set a $12.00 target price for the company in a report on Thursday, May 22nd. Stifel Nicolaus reduced their price objective on Inogen from $10.00 to $7.00 and set a "hold" rating for the company in a research note on Thursday, May 8th. Finally, B. Riley initiated coverage on Inogen in a research note on Monday, June 16th. They issued a "buy" rating and a $14.00 price objective for the company.
View Our Latest Research Report on INGN
Inogen Stock Performance
The company has a market capitalization of $172.36 million, a PE ratio of -5.57 and a beta of 1.66. The stock has a 50 day moving average price of $6.64 and a two-hundred day moving average price of $7.92.
Inogen (NASDAQ:INGN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The medical technology company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.27. The business had revenue of $82.28 million for the quarter, compared to analyst estimates of $79.57 million. Inogen had a negative return on equity of 14.76% and a negative net margin of 8.08%. Sell-side analysts predict that Inogen, Inc will post -1.73 earnings per share for the current year.
Hedge Funds Weigh In On Inogen
Hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC raised its position in Inogen by 5,738.9% in the 1st quarter. GAMMA Investing LLC now owns 5,547 shares of the medical technology company's stock valued at $400,000 after purchasing an additional 5,452 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Inogen during the fourth quarter valued at $56,000. Integrated Quantitative Investments LLC bought a new position in Inogen in the fourth quarter valued at about $92,000. Intech Investment Management LLC bought a new position in Inogen in the fourth quarter valued at about $94,000. Finally, Summit Global Investments bought a new position in Inogen in the fourth quarter valued at about $107,000. 89.94% of the stock is owned by institutional investors.
About Inogen
(
Get Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Featured Articles
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
